GSK Ellipta franchise expands

Share this article:
GSK and nonprofit shrink Big Data down to size
GSK Ellipta franchise expands

The FDA gave GlaxoSmithKline's efforts to create an Ellipta franchise a boost with the approval of the asthma treatment Arnuity Ellipta (fluticasone furoate).

The daily inhaled corticosteroid is approved for asthma maintenance among patients 12 and up, and joins the new respiratory series which includes Breo Ellipta (fluticasone furoate and vilanterol powder) and Anoro Ellipta (umeclidinium and vilanterol powder) for COPD in the US. Breo Ellipta is indicated for COPD and asthma in Europe.

The drugmaker's respiratory unit has been ailing—US respiratory sales fell 14% during the second quarter compared to the same period last year, and by 17% for the first six months of this year compared to the same period in 2013. Advair sales took a particular nosedive, falling 24% during the first six months of the year, to almost $1.7 billion, compared to the same six-month period in 2013. Advair's patent is scheduled to expire in 2017, and concerns are that this IP lapse will drive the product's performance even lower.

Payers and patients have not strongly taken to the new Ellipta drugs, and analysts anticipated a slow uptake even before Breo's approval because the Advair franchise has been so effective. GlaxoSmithKline has been urging investors to give the company's entire portfolio time to gain market confidence and build a stronger prescription base and is reaching out to consumers to do the same.

The company is also working towards filling out its offerings through efforts such as the Novartis asset swap in which GSK traded its oncology division in exchange for Novartis's vaccines business, yet respiratory remains a focal point.

“Without a pick-up in switching to new respiratory portfolio products, we struggle to see a compelling value proposition in GSK particularly as competition is poised to intensify with new respiratory entrants... as well as the expected introduction of Advair generics in 2017,” Leerink analyst Seamus Fernandez wrote in his second-quarter earnings assessment in July.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Channel


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...